Auxulin CEO and Co-Founder

 

Gary Ritz is a pharmacist and a practicing podiatrist. He has also been a type 1 diabetic for 37 years. Dr. Ritz received his bachelor's degree in pharmacy from Ohio State University. He then went on to become a doctor of podiatric medicine, receiving his DPM from the Ohio College of Podiatric Medicine, where he was also employed as an associate professor from 1987-1997, specializing in diabetic foot care. Over the course of his long career, Dr. Ritz has published many papers and articles regarding the care of diabetic patients. He has run his own podiatry clinic for over 30 years, during which time he estimates he has treated more than 10,000 patients with diabetes. He also has two sons with type 1 diabetes, and brings a crucial understanding of the challenges and stress experienced by parents of children with type 1 diabetes.

    Our Story

    Auxulin was founded by Dr. Gary Ritz and his son, Tommy Ritz. Gary has been living with T1D since 1984, and Tommy has been a T1D since 1998. Tired of their daily battles to manage their diabetes, which often resulted in prolonged periods of high blood sugar. The father/son duo sought a better way to combat hyperglycemia, which eventually led to the development of Auxulin. Auxulin is a supplement that, when used in conjunction with insulin and water, returned their high blood sugar levels to normal in a much faster time frame. They had several of their Type 1 friends and family members try it, and found it worked for them as well. Auxulin is an all-natural formulation. All of its active ingredients are widely available in food products and routinely ingested in some form by most people. Both Gary and Tommy used Auxulin regularly to help manage their diabetes, and want to bring Auxulin to the rest of the diabetic world.

    The Auxilin Team

    Investors/Partners

    Auxulin founders, working in conjunction with Dr. Jason McDevitt at the College of William & Mary, developed a formulation that safely and economically works in conjunction with insulin to reduce the duration and magnitude of hyperglycemic events. This patented technology was licensed from William & Mary to the company.